ClinicalTrials.gg
Enrolling by invitationNCT06573671Updated Sep 10, 2025

Histiocytosis in Injecting Drug Users

An observational study in Histiocytosis, sponsored by Tampere University Hospital. Enrolling by invitation at 1 site in Finland. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Tampere University Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
30
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The goal of this observational study is to describe a new disease condition of histiocytosis related to injecting drug use, its preconditions, symptoms, signs, findings, and prognosis in a detailed and systematic patient series in one referral center. The main question[s] it aims to answer are:

  • to find specific histologic features in different tissues to help the differential diagnosis from other histiocytoses
  • to describe the value of chitotriosidase activity to screen this condition
  • to describe the value of various tissue biopsies in confirming the diagnosis
  • to describe the nature of polyvinylpyrrolidone accumulation in tissue macrophages by novel special microscopic techniques
  • to find new tandem mass spectrometry methodology to prove polyvinylpyrrolidone accumulation in macrophages
  • to show that polyvinylpyrrolidone treatment activates macrophages to histiocytes and causes povidone accumulation within the cells in in vitro experiments
  • to evaluate the pathology of macrophage activation to histiocytes by transcriptomics

The patient history will be collected from the data produced by follow-up of cases followed up in a single center. A subgroup of participants will be given an opportunity to sign informed consent to give access to/donate blood and tissue samples to search for techniques to prove polyvinylpyrrolidone storage within histiocytes, and to search for transcriptomics signal(s) in histiocytes.

Researchers will compare blood and tissue samples from the biobank as controls.

Read the detailed description

Comprehensive patient data (disease history, findings, complications, laboratory findings, histopathology, and imaging) will be obtained from patient records of a single university hospital. Coded histiocytosis-positive tissue samples will be compared to biobank samples from corresponding tissues from healthy and other histiocytosis tissue samples to show polyvinylpyrrolidone storage with novel methodologies.

In addition, if a study participant who is followed up clinically, signs informed consent, monocytes are separated from a blood sample, differentiated to macrophages, and exposed to polyvinylpyrrolidone. Various novel methods will be utilized to explore polyvinylpyrrolidone within histiocytes.

02

Conditions studied

  • Histiocytosis

Keywords

  • intravenous
  • drug abuse
  • polyvinylpyrrolidone
  • PVP
03

In context

Histiocytosis

25 studies on the registry are indexed under Histiocytosis; 8 are open to participants now.

Browse Histiocytosis studies →

Lead sponsor

Tampere University Hospital is the lead sponsor of 212 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

Adult patients admitting to intravenous use of dissolved tablets (indicated for oral use) containing polyvinylpyrrolidone (PVP30) and positive tissue sample in any tissue biopsy compatible with features of histiocytosis caused by PVP30

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All identified adult patients in our records with a history of injecting drug use by dissolving tablets containing polyvinylpyrrolidone and (suspected) PVP-histiocytosis

Exclusion criteria

Exclusion Criteria:

  • Other histiocytosis diagnosed by tissue samples and clinical information
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
30 participants (estimated)
Target follow-up
40 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Injecting drug induced histiocytosis

    No intervention

    Diagnostic Test: Chitotriosidase · Diagnostic Test: Mass spectrometry · Diagnostic Test: scanning electron microscope with energy-dispersive X-ray spectroscopy · Diagnostic Test: Fluorescence microscopy · Diagnostic Test: Transcriptomics

Interventions

  • Diagnostic testChitotriosidase

    The amount of patients with increased chitotriosidase, and the extent of elevation of chitotriosidase

  • Diagnostic testMass spectrometry

    to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls

  • Diagnostic testscanning electron microscope with energy-dispersive X-ray spectroscopy

    to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls

  • Diagnostic testFluorescence microscopy

    to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls

  • Diagnostic testTranscriptomics

    To describe pathologic signals of polyvinylpyrrolidone-exposed in vitro histiocytes of injecting drug users compared to control samples

06

What researchers measure

Primary outcomes

  1. Frequency of disease manifestations

    To describe phenotype

    Time frame: 10 years

Secondary outcomes

  1. Frequency of elevated chitotriosidase activity

    Is chitotriosidase activity associated with polyvinylpyrrolidone histiocytosis

    Time frame: 10 years

  2. Mortality

    Mortality

    Time frame: 10 years

  3. Microscopic fluorescence positive tissue

    Search for specific polyvinylpyrrolidone fluorescence signal

    Time frame: 10 years

  4. Scanning electron microscope with energy-dispersive X-ray spectroscopy

    search for specific polyvinylpyrrolidone signal within cells

    Time frame: 10 years

  5. Pyrolysis mass spectrometry

    search for specific polyvinylpyrrolidone signal within cells

    Time frame: 10 years

  6. Transcriptomics analysis

    Search for immunologic pathway-specific abnormalities to guide treatment in cases compared with controls

    Time frame: 10 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Study data can only be acquired by proper inquiry to the national authority Findata by law

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2023 (actual). Primary completion is estimated for Dec 2030, 91 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2024
First posted
Aug 27, 2024
StartActual
May 29, 2023
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06573671
Responsible party
Sponsor
First posted
Aug 27, 2024
Start date
May 29, 2023
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Sep 10, 2025

Study contacts

Pasi I Nevalainen, MD, PhD
principal investigator · Senior consultant

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion